πͺπ²π²πΈπΉπ π¦π½πΌππΉπΆπ΄π΅π #6 π’
Patient-Centric Design: The Next Frontier In Drug Delivery
π£ Back in 2014, a roundtable discussion published in the Pharmaceutical Online magazine addressed the rising importance of patient-centric design in drug delivery within the pharmaceutical industry. The article emphasizes that true patient centricity goes beyond mere rhetoric and involves considering the end user from the inception of drug development through the entire product lifecycle.
β Ralph Lipp, President of Lipp Life Sciences LLC, underscored the significance of focusing on patients throughout drug development, stressing factors like safety, efficacy, portability, and social acceptability. He also added that improved patient outcomes stem from a comprehensive understanding of patient needs and interactions with delivery devices.
β Kurt Nielsen, at the time CTO of Catalent Pharma Solutions, highlighted the importance of easy self-administration and emphasized the need to address diverse patient populations' needs. He also stated that a patient-centric design approach promotes enhanced adherence to medication regimens and reduces healthcare costs.
β Robert Becker, at the time CRO of Aptalis Pharma, emphasized the potential cost savings associated with patient-centric formulations, which could influence payer coverage decisions, suggesting that insurers could prioritize improvements in patient outcomes as a measure for reimbursement.
π° The article also discussed the dilemma faced by pharmaceutical companies regarding the timing of drug release vis-Γ -vis device optimization. While rapid market entry may benefit patients, a subpar delivery device could undermine efforts. Balancing these concerns involves weighing potential benefits against associated risks.
π In summary, this 2014 article advocates for a holistic approach to drug delivery design, one that prioritizes patient needs, enhances adherence, and ultimately improves healthcare outcomes. It echoes the tremendous efforts made by different stakeholders over the years to achieve the current status quo for patient-centric drug product development.
π Article by: Ed Miseta, Chief Editor, Clinical Leader
π Source: Life Science Leader